IntelGenx (TSXV:IGX; OTCQX:IGXT) plans to demonstrate the capabilities of its contract development and manufacturing organization (CDMO) services and its VersaFilm and VetaFilm oral film technologies, at CPhI North America on April 30 to May 2 in Chicago.
VersaFilm and VetaFilm are IntelGenx’s oral drug delivery technology platforms for human and veterinary applications, respectively. They enable the development of oral films with the potential to improve absorption, accelerate onset of action, reduce side effects, ease administration and improve patient compliance.
In a statement, Horst Zerbe, president and CEO of IntelGenx, said the conference is an excellent forum for the company to demonstrate to the pharma world its CDMO capabilities and how its oral film technologies can help address unmet medical needs.
